Comparative Pharmacology
Head-to-head clinical analysis: ACHROMYCIN V versus DORYX MPC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACHROMYCIN V versus DORYX MPC.
ACHROMYCIN V vs DORYX MPC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bacteriostatic; binds reversibly to 30S ribosomal subunit, inhibits protein synthesis by blocking aminoacyl-tRNA binding to mRNA-ribosome complex.
Doxycycline, a tetracycline antibiotic, inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, blocking aminoacyl-tRNA binding to the mRNA-ribosome complex.
250-500 mg orally every 6 hours
100 mg orally twice daily on day 1, then 100 mg once daily; alternatively, 200 mg orally once daily.
None Documented
None Documented
Terminal elimination half-life is 6-12 hours in patients with normal renal function; prolonged in renal impairment (up to 48-72 hours in anuria).
Terminal elimination half-life: 18–22 hours in adults with normal renal function; prolonged in renal impairment (up to 25–30 hours) or with hepatic dysfunction.
Renal (60% unchanged in urine via glomerular filtration), biliary/fecal (40% as active drug and metabolites, with a portion undergoing enterohepatic recirculation).
Renal (approximately 40% as unchanged drug via glomerular filtration), fecal/biliary (up to 30% as conjugated or inactive metabolites), remainder metabolized.
Category C
Category C
Tetracycline Antibiotic
Tetracycline Antibiotic